Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.
复制标题

DOI:
10.1615/critrevimmunol.2013007046
复制
发表时间:
2013
影响因子:
1.3
通讯作者:
Miller SD
Miller SD
中科院分区:
医学4区
文献类型:
--
作者:
Smarr CB;Bryce PJ;Miller SD

文献摘要

参考文献

被引文献

相似文献

过敏性疾病是一个日益严重的健康问题,特别是在发达国家。治疗过敏性疾病的标准临床方法侧重于过敏原避免和症状控制,但很少解决疾病的潜在Th 2偏倚。特异性免疫治疗(SIT)包括控制过敏原的管理,然而,已被证明成功地诱导脱敏和耐受性的抗原特异性的方式为各种Th 2介导的疾病。本文综述了目前SIT方法诱导耐受的机制,并讨论了修改SIT安全性和有效性的尝试。这些改进集中在SIT的三个主要方面:抗原给药途径,抗原修饰以去除变应原表位并减少不良事件,以及用于诱导耐受性和/或从Th 2到Th 1和调节性T细胞(Treg)表型的免疫偏离的佐剂的选择。SIT的这些最新发展的综合为更稳健的治疗提供了相当大的希望,具有改善的安全性特征,以改善过敏性疾病的解决方案及其相关成本。
Allergic diseases are an increasing health concern, particularly in the developed world. The standard clinical approach to treatment of allergic disease focuses on allergen avoidance and symptom control but does little to address the underlying Th2 bias of disease. Specific immunotherapy (SIT) consisting of controlled administration of allergen, however, has been demonstrated to successfully induce desensitization and tolerance in an antigen-specific manner for a variety of Th2-mediated diseases. This review focuses on the mechanisms by which current SIT approaches induce tolerance as well as discussing attempts to modify the safety and efficacy of SIT. These refinements focus on three major aspects of SIT: the route of antigen administration, modification of the antigen to remove allergenic epitopes and reduce adverse events and choice of adjuvant used to induce tolerance and/or immune deviation from Th2 to Th1 and regulatory T cell (Treg) phenotypes. Synthesis of these recent developments in SIT provides considerable promise for more robust therapies with improved safety profiles to improve resolution of allergic disease and its associated costs.
DOI: 10.1111/j.1600-6143.2012.04203.x
发表时间: 2012-11
期刊: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
影响因子: --
作者:
Chen G;Kheradmand T;Bryant J;Wang S;Tasch J;Wang JJ;Zhang Z;Luo X
通讯作者: Luo X
DOI: 10.1016/j.jaci.2004.02.006
发表时间: 2004-06-01
影响因子: 14.2
作者:
Bernstein, DI;Wanner, M;Liss, GM
通讯作者: Liss, GM
DOI: 10.1016/j.vaccine.2012.06.049
发表时间: 2012-08-17
期刊: VACCINE
影响因子: 5.5
作者:
Batard, T.;Zimmer, A.;Moingeon, P.
通讯作者: Moingeon, P.
DOI: 10.1056/nejmoa1200435
发表时间: 2012-07-19
期刊: The New England journal of medicine
影响因子: --
作者:
Burks AW;Jones SM;Wood RA;Fleischer DM;Sicherer SH;Lindblad RW;Stablein D;Henning AK;Vickery BP;Liu AH;Scurlock AM;Shreffler WG;Plaut M;Sampson HA;Consortium of Food Allergy Research (CoFAR)
通讯作者: Consortium of Food Allergy Research (CoFAR)
DOI: 10.1002/eji.200323329
发表时间: 2003-10-01
影响因子: 5.4
作者:
Akdis, CA;Kussebi, F;Alkan, SS
通讯作者: Alkan, SS